Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The announced sales of three healthcare ... looking to expand in non-healthcare areas, says Kalorama Information. ... research firm says that  Siemens is the third largest ... of the IVD market , with 5.5 billion in ... composition would likely affect IVD market shares.  ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s ... D.C. science community to the UMBC campus for a ... the Protein Society, will take place from 9 a.m. ... Through discussion, presentations and workshops, the free symposium ... their role in the industry and the future of ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Whitehouse ... officially joined the Morris County (New Jersey) Chamber ... is a leading business organization in the North ... to further engage some key clients in the ... in the geographic area. Membership enables Whitehouse Laboratories ...
(Date:11/26/2014)... 2014 Continuing its award-winning streak, Nerium ... prestigious MarCom Awards for outstanding creative achievement by its ... MarCom Award, the organization’s top honor, in the Branding ... held in April of this year. The event showcased ... Additionally, Nerium was awarded a Gold MarCom Award in ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... How does one visualize thought? , ,Well, by pressing ... thinner than a human hair against the membrane of ... identify the electric current flowing through individual ion channels on ... method, and it allows a peek at the electrical activity ...
... flocked to the DEMO conference last week in Scottsdale. Many ... the past 15 years have been introduced at this confab, ... joined by more than 250 million readers, listeners and viewers ... through which we can look at the state of the ...
... this week reported the best annual financial results in the company's ... exceeded all of its stated fiscal expectations. , ,Third Wave reported ... million for the year ended December 31, compared to total revenues ... 2003. , ,The company reported total revenues of $8.1 million ...
Cached Biology Technology:Prairie Technologies works with UW engineer to visualize the brain 2In search of the next big thing at DEMO 2In search of the next big thing at DEMO 3Third Wave boosts numbers in latest report 2Third Wave boosts numbers in latest report 3Third Wave boosts numbers in latest report 4
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
(Date:11/3/2014)... Nov. 3, 2014 Research and Markets ... Therapy - Technologies, Markets and Companies" to their offering. ... technologies and methods, which have already started to play an ... transplantation is replacing the old fashioned bone marrow transplants. Role ... is bound to become a part of medical practice. ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... and the Japan Synchrotron Radiation Research Institute (JASRI) have ... Electron Laser (XFEL) facility in Harima, the first such ... whole world. Nicknamed "SACLA" (SPring-8 Angstrom Compact Free Electron ... unique window onto the minuscule structure of molecules and ...
... Agricultural Research and Development) is carrying out research, ... palm crops through genetic enhancement. Its Biotechnology Department ... technique known as Marker-Assisted Selection (MAS) with the ... this crop. This technique enables detecting new genes ...
... 2011 Researchers from Canada and the United ... 2011 Scientific Meeting that they have uncovered a ... whether the estrogens in their bodies take a ... researchers tested a nutritional combination of indole-3 carbinol, ...
Cached Biology News:RIKEN and JASRI unveil 'SACLA', Japan's first X-ray free electron laser 2Neiker-Tecnalia research -- to obtain more productive, resistant and sustainable oil palms 2Neiker-Tecnalia research -- to obtain more productive, resistant and sustainable oil palms 3Clinical study suggests estrogen levels and breast health can be altered 2Clinical study suggests estrogen levels and breast health can be altered 3
... Klenow fragment is a proteolytic ... DNA Polymerase I which ... 5 exonuclease activity, but has ... Klenow retains the polymerization fidelity ...
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
Biology Products: